RV03 is a product of Intellect's RECALL-VAX platform technology that is designed to produce antibodies that specifically target the unique molecular signatures ("neoepitopes") that exist only in products of protein metabolism. Relevant examples include the free amino terminus of amyloid (Amyloid beta) at the beta secretase site produced from the amyloid precursor protein and the free C terminus of delta tau from intact microtubule associated protein Tau produced by executioner caspases. In contrast to other Alzheimer's vaccines in development that target single proteins, RV03 is uniquely capable of eliciting an immune response against both Amyloid beta and delta tau at the same time.
"My laboratory was the first to demonstrate that Amyloid beta facilitates the accumulation of Tau through a variety of mechanisms including by interfering with proteasome function and by reducing a key chaperone protein called Chip," said Dr. LaFerla. "Therefore, we were excited to be asked to participate in the seminal work being done at Intellect Neurosciences to test the therapeutic and prophylactic potential of RV03. Our combined research aims to develop the first dual vaccine against these two important therapeutic targets to prevent the irreversible damage and death of nerve cells caused by these two proteins."
Intellect Neurosciences' RECALL-VAX platform was recently featured in the industry publication, Fierce Vaccines (http://www.fiercevaccines.com/story/intellect-neurosciences-chases-holy-grail-alzheimers-preventive
|SOURCE Intellect Neurosciences, Inc.|
Copyright©2010 PR Newswire.
All rights reserved